|
Gene expression and disease control with XelOX therapy |
|||
| CR+PR+SD |
PD |
total |
|
|
|
|||
| TS ≤ median |
25 |
5 |
30 |
|
|
|||
| TS > median |
17 |
13 |
30 |
|
|
|||
| ERCC1 ≤ 75th% |
35 |
10 |
45 |
|
|
|||
| ERCC1 > 75th% |
8 |
7 |
15 |
|
Six subjects were not assessable for response; therefore, only 60 subjects each with informative TS and ERCC1 samples from metastatic tumor tissue are included in the analysis between gene expression and disease control. The Fisher exact test p-value was 0.047 for TS and 0.099 for ERCC1. | |||
Uchida et al. BMC Cancer 2008 8:386 doi:10.1186/1471-2407-8-386 |
|||